Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells

Abstract

Increases in the abundance of cathepsin B transcript and protein with increased tumor grade and changes in subcellular localization and activity of this enzyme. We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade. To investigate the role of cystatin C in the invasion of brain tumor cells, we stably transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct of human cystatin C in the sense orientation or an empty vector. Clones expressing sense-cystatin C cDNA had higher cystatin C mRNA and protein levels than did control cells. Sense-transfected cells were also markedly less invasive than control cells in a Matrigel invasion assay and in a coculture assay of SNB19 spheroids and fetal rat brain aggregates. Finally, the sense-transfected cells did not form tumors in nude mice upon intracerebral injection. These results strongly implicate cystatin C in the invasiveness of human glioblastoma cells and suggest that sense transcripts of cystatin C may prove useful in cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Abrahamson M, Barrett AJ, Salvesen G, Grubb A . 1986 J. Biol. Chem. 261: 11282–11289

  • Abrahamson M, Grubb A, Glafsson I, Lundwall A . 1987 FEBS Lett. 216: 229–233

  • Barrett AJ . 1987 Trends Biochem. Sci. 12: 193–196

  • Bobek LA, Levine MJ . 1992 Crit. Rev. Oral Biol. Med. 3: 307–332

  • Calkins CC, Sameni M, Koblinski J, Sloane BF, Moin K . 1998 J. Histochem. Cytochem. 46: 745–751

  • Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159

  • Corticchiato O, Cajot JF, Abrahamson M, Chan SJ, Keppler D, Sordat B . 1992 Int. J. Cancer 52: 645–652

  • Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J, Mach L . 1999 Int. J. Cancer 83: 526–531

  • Cox JL, Sexton PS, Green TJ, Darmani NA . 1999 Melanoma Res. 9: 369–374

  • Foekens JA, Kos J, Peters HA, Krasoveck M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG . 1998 J. Clin. Oncol. 16: 1013–1021

  • Gaumann A, Hansen T, Kohler HH, Kommoss F, Mann W, Maurer J, Kirkpatrick CJ, Kriegsmann J . 2001 Pathol. Res. Pract. 197: 257–262

  • Hawley-Nelson P, Roop DR, Cheng CK, Krieg TM, Yuspa SH . 1988 Mol. Carcinol. 1: 202–211

  • Heidtmann HH, Hofmann M, Jacob E, Erbil C, Havemann K, Schwartz-Albiez R . 1989 Cancer Res. 49: 6960–6965

  • Heidtmann HH, Havemann K, Schwartz-Albiez R . 1992 Br. J. Cancer 65: 154–156

  • Hirai K, Yokoyama M, Asano G, Tanaka S . 1999 Hum. Pathol. 30: 680–686

  • Huh CT, Hakansson K, Nathanson CM, Thorgeirsson UP, Jonsson N, Grubb A, Abrahamson M, Karlsson S . 1999 Mol. Pathol. 52: 332–340

  • Keppler D, Waridel P, Abrahamson M, Bachmann D, Berdoz J, Sordat B . 1994 Biochim. Biophys. Acta 1226: 117–125

  • Konduri SD, Rao CN, Chandrasekar N, Tasiou A, Mohanam S, Kim Y, Lakka SS, Dinh D, Olivero WC, Gujrati M, Foster DC, Kisiel W, Rao JS . 2001 Oncogene 20: 6938–6945

  • Kos J, Werle B, Lah T, Brunner N . 2000 Int. J. Biol. Markers 15: 84–89

  • Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I . 1997 Clin. Cancer Res. 3: 1815–1822

  • Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, Brunner N . 1998 Clin. Cancer Res. 4: 1511–1516

  • Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N . 2000 Clin. Cancer Res. 6: 505–511

  • Krepela E, Prochazka J, Karova B, Cermak J, Roubkova H . 1998 Neoplasma 45: 318–331

  • Laemmli NK . 1970 Nature 227: 680–685

  • Lah TT, Kokalj-Kunovar M, Kastelic L, Babnik J, Stolfa A, Rainer S, Turk V . 1992 Cancer Lett. 61: 243–253

  • Lah TT, Cercek M, Blejec A, Kos J, Gorodetsky E, Somers R, Daskai I . 2000 Clin. Cancer Res. 6: 578–584

  • Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S . 1980 Nature 284: 67–68

  • Liotta LA, Steeg PS, Stetler-Stevenson WG . 1991 Cell 64: 327–336

  • Mangge H, Liebmann P, Tanil H, Herrmann J, Wagner C, Gallistl S, Schauenstein K, Erwa W . 2000 Clin. Chim. Acta. 300: 195–202

  • Merz GS, Benedikz E, Schwenk V, Johansen TE, Vogel LK, Rushbrook JI, Wisniewski HM . 1997 J. Cell Physiol. 173: 423–432

  • Mignatti P, Rifkin DB . 1993 Physiol. Rev. 73: 161–195

  • Mort JS, Recklies AD, Poole AR . 1980 Biochem. Biophys Acta. 614: 134–143

  • Murnane MJ, Sheahan K, Ozdemirli M, Shuja S . 1991 Cancer Res. 51: 1137–1142

  • Pavlova A, Krupa JC, Mort JS, Abrahamson M, Bjork I . 2000 FEBS Lett. 487: 156–160

  • Pederson PH, Marienhagen K, Mork S, Bjerkvig R . 1993 Cancer Res. 53: 5158–5165

  • Qian F, Bajkowski AS, Steiner DF, Chan SJ, Frankfater A . 1989 Cancer Res. 49: 4870–4875

  • Randers E, Erlandsen EJ . 1999 Clin. Chem. Lab. Med. 37: 389–395

  • Schmitt M, Janicke H, Graeff H . 1992 Fibrinolysis 6: 3–26

  • Sexton PS, Cox JL . 1997 Melanoma Res. 7: 97–101

  • Sheahan K, Shuja S, Murnane MJ . 1989 Cancer Res. 49: 3809–3814

  • Sloane BF . 1990 Semin. Cancer Biol. 1: 137–152

  • Sloane BF, Moin K, Lah TT . 1994 Aspects of the Biochemistry and Molecular Biology of Tumors Vol 2: Pretlow TG and Pretlow TH (eds) New York: Academic Press pp 411–466

    Google Scholar 

  • Sloane BF, Moin K, Krepela E, Rozhin J . 1990 Cancer Metastasis Rev. 9: 333–352

  • Stabuc B, Vrhovec L, Stabuc-Silih M, Cizej TE . 2000 Clin. Chem. 46: 193–197

  • Strojan P, Budihna M, Smid L, Svetic B, Vrhovec I, Kos J, Skrk J . 2000 Clin. Cancer Res. 6: 1052–1062

  • Strojnik T, Kos J, Zidanik B, Golouh R, Lah T . 1999 Clin. Cancer Res. 5: 559–567

  • Sukoh N, Abe S, Nakajima I, Ogura S, Isobe H, Inoue K, Kawakami Y . 1994 Virchows Arch. 424: 33–38

  • Terada T, Ohta T, Minato H, Nakanuma Y . 1995 Hum. Pathol. 26: 746–752

  • Towbin H, Staehelim T, Gordon J . 1979 Proc. Natl. Acad. Sci. USA 76: 4350–4354

  • Watanabe M, Higashi T, Watanabe A, Osawa T, Sato Y, Kimura Y, Tominaga S, Hashimoto N, Yoshida Y, Morimoto S . 1989 Biochem. Med. Metab. Biol. 42: 21–29

  • Werle B, Lotterle H, Schanzenbacher U, Lah TT, Kalman E, Kayser K, Bulzebruck H, Schirren J, Krasovec M, Kos J, Spiess E . 1999 Br. J. Cancer 81: 510–519

  • Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y, Inokuchi M, Asano G . 2001 Surg. Today 31: 385–389

  • Yoshimura K, Tsuchida T, Kawamoto K . 2000 Oncol. Rep. 7: 27–31

Download references

Acknowledgements

This work was supported in part by a National Institute for Health grant CA 76350 to Jasti S Rao.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jasti S Rao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Konduri, S., Yanamandra, N., Siddique, K. et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21, 8705–8712 (2002). https://doi.org/10.1038/sj.onc.1205949

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205949

Keywords

This article is cited by

Search

Quick links